Mineralys Therapeutics, Common Stock Fundamentals
| MLYS Stock | 11.87 0.73 5.79% |
Mineralys Therapeutics, Common fundamentals help investors to digest information that contributes to Mineralys Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Mineralys Stock. The fundamental analysis module provides a way to measure Mineralys Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mineralys Therapeutics, stock.
At this time, Mineralys Therapeutics,'s Net Interest Income is comparatively stable compared to the past year. Interest Expense is likely to gain to about 2 M in 2024, despite the fact that Operating Income is likely to grow to (80.4 M). Mineralys | Select Account or Indicator |
Mineralys Therapeutics, Common Company Return On Asset Analysis
Mineralys Therapeutics,'s Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mineralys Therapeutics, Return On Asset | -0.39 |
Most of Mineralys Therapeutics,'s fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mineralys Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Mineralys Total Assets
Total Assets |
|
Based on the latest financial disclosure, Mineralys Therapeutics, Common has a Return On Asset of -0.3856. This is 95.59% lower than that of the Biotechnology sector and 98.37% lower than that of the Health Care industry. The return on asset for all United States stocks is 175.43% higher than that of the company.
Mineralys Therapeutics, Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mineralys Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Mineralys Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mineralys Therapeutics, competition to find correlations between indicators driving Mineralys Therapeutics,'s intrinsic value. More Info.Mineralys Therapeutics, Common is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Mineralys Therapeutics,'s Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Mineralys Therapeutics, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Mineralys Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in return on asset category among its peers.
Mineralys Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mineralys Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mineralys Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Mineralys Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.39 | ||||
| Current Valuation | 593.85 M | ||||
| Shares Outstanding | 49.77 M | ||||
| Shares Owned By Insiders | 2.60 % | ||||
| Shares Owned By Institutions | 97.40 % | ||||
| Number Of Shares Shorted | 1.39 M | ||||
| Price To Book | 2.49 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) | ||||
| Total Debt | 10.48 M | ||||
| Book Value Per Share | 4.76 X | ||||
| Cash Flow From Operations | (81.17 M) | ||||
| Short Ratio | 10.39 X | ||||
| Earnings Per Share | (3.31) X | ||||
| Target Price | 32.57 | ||||
| Number Of Employees | 28 | ||||
| Market Capitalization | 590.75 M | ||||
| Total Asset | 251.64 M | ||||
| Retained Earnings | (124.71 M) | ||||
| Working Capital | 238.62 M | ||||
| Net Asset | 251.64 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.